• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Monday's Intraday Session

    5/15/23 1:31:29 PM ET
    $ATNX
    $AUTL
    $BBLN
    $ELOX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ATNX alert in real time by email

    Gainers

    • Eloxx Pharmaceuticals (NASDAQ:ELOX) stock rose 36.0% to $4.84 during Monday's regular session. Trading volume for Eloxx Pharmaceuticals's stock is 141.8K as of 13:30 EST. This is 58.9% of its average full-day volume over the last 100 days. The company's market cap stands at $10.4 million.
    • Vaxart (NASDAQ:VXRT) stock rose 31.42% to $1.38. Trading volume for this security as of 13:30 EST is 5.1 million, which is 411.4% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $187.1 million.
    • Sarepta Therapeutics (NASDAQ:SRPT) shares rose 28.1% to $153.98. Trading volume for this security as of 13:30 EST is 5.4 million, which is 336.0% of its average full-day volume over the last 100 days. The company's market cap stands at $14.3 billion.
    • Scilex Holding (NASDAQ:SCLX) stock rose 23.9% to $6.7. As of 13:30 EST, Scilex Holding's stock is trading at a volume of 1.0 million, which is 167.4% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $977.3 million.
    • Equillium (NASDAQ:EQ) shares moved upwards by 22.01% to $0.71. Equillium's stock is trading at a volume of 361.2K shares as of 13:30 EST. This is 214.6% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $24.4 million. As per the press release, Q1 earnings came out 2 days ago.
    • Autolus Therapeutics (NASDAQ:AUTL) stock moved upwards by 21.97% to $2.5. As of 13:30 EST, this security is trading at a volume of 2.3 million shares, making up 497.0% of its average full-day volume over the last 100 days. The company's market cap stands at $432.7 million.

    Losers

    • Athenex (NASDAQ:ATNX) shares decreased by 63.6% to $0.41 during Monday's regular session. Athenex's stock is trading at a volume of 2.3 million shares as of 13:30 EST. This is 2271.7% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $3.5 million.
    • Larimar Therapeutics (NASDAQ:LRMR) stock fell 30.44% to $3.52. Trading volume for Larimar Therapeutics's stock is 1.5 million as of 13:30 EST. This is 753.4% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $152.3 million. As per the news, the Q1 earnings report came out today.
    • NovaBay Pharmaceuticals (AMEX:NBY) stock decreased by 20.77% to $0.77. The current volume of 544.2K shares is 469.9% of NovaBay Pharmaceuticals's average full-day volume over the last 100 days (last updated at 13:30 EST). The company's market cap stands at $1.5 million. As per the press release, Q1 earnings came out 2 days ago.
    • Babylon Holdings (NYSE:BBLN) shares fell 20.1% to $0.85. The current volume of 2.6 million shares is 830.6% of Babylon Holdings's average full-day volume over the last 100 days (last updated at 13:30 EST). The market value of their outstanding shares is at $21.2 million. The company's, Q1 earnings came out 3 days ago.
    • Impel Pharmaceuticals (NASDAQ:IMPL) stock fell 19.14% to $1.23. Impel Pharmaceuticals's stock is trading at a volume of 100.2K shares as of 13:30 EST. This is 201.2% of its average full-day volume over the last 100 days. The company's market cap stands at $29.1 million. As per the news, the Q1 earnings report came out yesterday.
    • Kineta (NASDAQ:KA) shares fell 17.37% to $3.26. The market value of their outstanding shares is at $27.8 million. As per the news, the Q1 earnings report came out 2 days ago. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ATNX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ATNX
    $AUTL
    $BBLN
    $ELOX

    CompanyDatePrice TargetRatingAnalyst
    Equillium Inc.
    $EQ
    3/13/2026$12.00Buy
    Roth Capital
    Equillium Inc.
    $EQ
    2/25/2026$5.00Buy
    Stifel
    Autolus Therapeutics plc
    $AUTL
    2/17/2026$9.00Buy
    H.C. Wainwright
    Sarepta Therapeutics Inc.
    $SRPT
    1/28/2026$20.00Equal Weight
    Barclays
    Sarepta Therapeutics Inc.
    $SRPT
    12/9/2025$32.00Outperform
    Wedbush
    Sarepta Therapeutics Inc.
    $SRPT
    11/5/2025$26.00Neutral → Outperform
    Mizuho
    Sarepta Therapeutics Inc.
    $SRPT
    9/22/2025$50.00Market Perform → Outperform
    BMO Capital Markets
    Sarepta Therapeutics Inc.
    $SRPT
    7/29/2025$22.00Underweight → Equal Weight
    Barclays
    More analyst ratings

    $ATNX
    $AUTL
    $BBLN
    $ELOX
    SEC Filings

    View All

    Scilex Holding Company filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Scilex Holding Co (0001820190) (Filer)

    3/13/26 12:59:15 PM ET
    $SCLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Equillium Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities

    8-K - Equillium, Inc. (0001746466) (Filer)

    3/13/26 8:15:19 AM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Scilex Holding Company filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Scilex Holding Co (0001820190) (Filer)

    3/13/26 6:03:22 AM ET
    $SCLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ATNX
    $AUTL
    $BBLN
    $ELOX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Roth Capital initiated coverage on Equillium with a new price target

    Roth Capital initiated coverage of Equillium with a rating of Buy and set a new price target of $12.00

    3/13/26 8:47:00 AM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Stifel initiated coverage on Equillium with a new price target

    Stifel initiated coverage of Equillium with a rating of Buy and set a new price target of $5.00

    2/25/26 7:52:10 AM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright initiated coverage on Autolus Therapeutics with a new price target

    H.C. Wainwright initiated coverage of Autolus Therapeutics with a rating of Buy and set a new price target of $9.00

    2/17/26 8:13:55 AM ET
    $AUTL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ATNX
    $AUTL
    $BBLN
    $ELOX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Scilex Holding Company Files Federal Securities Fraud Lawsuit Seeking Recovery of Approximately Ninety-Six (96) Million Misappropriated Collateral Shares of Datavault AI, Inc. from Marc Wade, The St. James Bank & Trust Company Ltd., Omega & Corinth Group Ltd., The Bank of New York Mellon Corporation, and Related Parties

    PALO ALTO, Calif., March 13, 2026 (GLOBE NEWSWIRE) -- Scilex Holding Company ("Scilex" or the "Company") (NASDAQ:SCLX), an innovative revenue-generating company focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, today announced that it has filed a complaint (the "Complaint") in the United States District Court for the Central District of California against Marc Wade, The St. James Bank & Trust Company Ltd. ("St. James Bank"), Omega & Corinth Group Ltd., and related parties (collectively, the "Wade Defendants"), alleging a scheme involving the unauthorized tr

    3/13/26 11:16:18 AM ET
    $SCLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Equillium Announces $35 Million Financing with RA Capital Management

    Capital strengthens the advancement of EQ504 through key clinical milestones Anticipated net proceeds, along with existing cash and cash equivalents, expected to extend cash runway into 2029 LA JOLLA, Calif., March 13, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. ("Equillium" or the "Company") (NASDAQ:EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that it has entered into a definitive securities purchase agreement with RA Capital Management that will provide approximately $35 million in gross proceeds to Equillium. Pursuant to the terms of the securities purchase agreement, the Company will issue approximately

    3/13/26 8:00:00 AM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vaxart Provides Business Update and Reports Full Year 2025 Financial Results

    Topline data from 400-person sentinel cohort of the Phase 2b COVID-19 trial anticipated early Q2 2026 Published positive clinical results in the first quarter of 2026 demonstrating oral norovirus vaccine candidate was safe and immunogenic in lactating women and resulted in passive transfer of antibodies to their infants via breast milk Cash, cash equivalents and investments of $63.8 million as of December 31, 2025; Runway into second quarter of 2027 Conference call today at 4:30 p.m. ET Live stockholder fireside chat scheduled for March 13, 2026 at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX:VXRT) ("Vaxart" or the "Company"), a clin

    3/12/26 4:05:00 PM ET
    $VXRT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ATNX
    $AUTL
    $BBLN
    $ELOX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: Sr. Vice President and COO Zedelmayer Christine exercised 185,937 shares at a strike of $0.76 and sold $328,104 worth of shares (185,937 units at $1.76) (SEC Form 4)

    4/A - Equillium, Inc. (0001746466) (Issuer)

    3/11/26 8:25:15 PM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sr. Vice President and COO Zedelmayer Christine exercised 152,361 shares at a strike of $0.79 and sold $362,438 worth of shares (181,219 units at $2.00), decreasing direct ownership by 32% to 62,586 units (SEC Form 4)

    4 - Equillium, Inc. (0001746466) (Issuer)

    3/11/26 8:11:26 PM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Wong Ryan Ho-Yan covered exercise/tax liability with 275 shares, decreasing direct ownership by 0.20% to 135,320 units (SEC Form 4)

    4 - Sarepta Therapeutics, Inc. (0000873303) (Issuer)

    3/11/26 8:08:03 PM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATNX
    $AUTL
    $BBLN
    $ELOX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for AMONDYS 45 issued to SAREPTA THERAPS INC

    Submission status for SAREPTA THERAPS INC's drug AMONDYS 45 (SUPPL-8) with active ingredient CASIMERSEN has changed to 'Approval' on 07/11/2024. Application Category: NDA, Application Number: 213026, Application Classification: Labeling

    7/12/24 4:40:36 AM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    June 20, 2024 - FDA Expands Approval of Gene Therapy for Patients with Duchenne Muscular Dystrophy

    For Immediate Release: June 20, 2024 Today, the U.S. Food and Drug Administration expanded the approval of Elevidys (delandistrogene moxeparvovec-rokl), a gene therapy for the treatment of Duchenne muscular dystrophy (DMD) for ambulatory and non-ambulatory individuals 4 years of age and older with DMD with a confirmed mutation in the DMD gene.  Elevidys was previously approved under accelerated approval for amb

    6/20/24 5:24:42 PM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for VYONDYS 53 issued to SAREPTA THERAPS INC

    Submission status for SAREPTA THERAPS INC's drug VYONDYS 53 (SUPPL-11) with active ingredient GOLODIRSEN has changed to 'Approval' on 06/04/2024. Application Category: NDA, Application Number: 211970, Application Classification: Labeling

    6/5/24 4:41:31 AM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATNX
    $AUTL
    $BBLN
    $ELOX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    * Director by Deputization Flynn James E bought $25,000,000 worth of shares (5,000,000 units at $5.00) (SEC Form 4)

    4 - Larimar Therapeutics, Inc. (0001374690) (Issuer)

    3/2/26 7:46:04 PM ET
    $LRMR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Hamilton Thomas Edward bought $500,000 worth of shares (100,000 units at $5.00), increasing direct ownership by 18% to 664,798 units (SEC Form 4)

    4 - Larimar Therapeutics, Inc. (0001374690) (Issuer)

    3/2/26 4:30:41 PM ET
    $LRMR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Thomas Frank E bought $25,000 worth of shares (5,000 units at $5.00), increasing direct ownership by 250% to 7,000 units (SEC Form 4)

    4 - Larimar Therapeutics, Inc. (0001374690) (Issuer)

    3/2/26 4:30:36 PM ET
    $LRMR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATNX
    $AUTL
    $BBLN
    $ELOX
    Leadership Updates

    Live Leadership Updates

    View All

    Scilex Holding Company Appoints Kasowitz LLP as Litigation and Intellectual Property Counsel

    PALO ALTO, Calif., Jan. 02, 2026 (GLOBE NEWSWIRE) -- Scilex Holding Company ("Scilex" or the "Company") (NASDAQ:SCLX), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, announced that it has appointed Kasowitz LLP and its founding partner Marc Kasowitz as the Company's litigation and intellectual property counsel. Kasowitz LLP will advise Scilex on complex commercial litigation, patent litigation, intellectual property enforcement and defense, licensing matters, and strategic intellectual property governance as the C

    1/2/26 9:00:00 AM ET
    $SCLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    NeuraClick Welcomes Biotech Veteran Daniel M. Bradbury as Strategic and Metabolic Programs Advisor

    SAN DIEGO, Sept. 23, 2025 (GLOBE NEWSWIRE) -- NeuraClick, Inc., an innovative, preclinical-stage biopharmaceutical company reimagining patient health through the development of novel, long-acting neurotherapeutics, today announced the appointment of industry veteran and biotech executive Daniel M. Bradbury as Strategic and Metabolic Programs Advisor. "We are thrilled to welcome Dan to NeuraClick," said Dr. Subhi Marwari, Chief Executive Officer. "For an early-stage venture, experienced guidance is essential, and Dan's deep expertise in company building and metabolic therapeutics will be invaluable as we advance our pipeline. He is a phenomenal coach on this journey, helping us navigat

    9/23/25 5:30:46 AM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NovaBay Pharmaceuticals Issues a Reminder of Important Information Regarding the Pending Special Dividend and Upcoming 2025 Annual Meeting

    EMERYVILLE, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) -- NovaBay® Pharmaceuticals, Inc. (NYSE:NBY) (the "Company") previously announced a one-time special cash dividend of $0.80 per share for the Company's common stock. The special cash dividend will be payable on September 29, 2025 to stockholders of record as of the close of business on September 15, 2025. Because the payment of the special dividend represents more than 25% of the price of the Company's common stock, NYSE American advised the Company that its common stock will trade with "due bills" representing an assignment of the right to receive the special dividend from the record date of September 15, 2025 through the close of tradi

    9/18/25 4:30:00 PM ET
    $NBY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATNX
    $AUTL
    $BBLN
    $ELOX
    Financials

    Live finance-specific insights

    View All

    Vaxart Provides Business Update and Reports Full Year 2025 Financial Results

    Topline data from 400-person sentinel cohort of the Phase 2b COVID-19 trial anticipated early Q2 2026 Published positive clinical results in the first quarter of 2026 demonstrating oral norovirus vaccine candidate was safe and immunogenic in lactating women and resulted in passive transfer of antibodies to their infants via breast milk Cash, cash equivalents and investments of $63.8 million as of December 31, 2025; Runway into second quarter of 2027 Conference call today at 4:30 p.m. ET Live stockholder fireside chat scheduled for March 13, 2026 at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX:VXRT) ("Vaxart" or the "Company"), a clin

    3/12/26 4:05:00 PM ET
    $VXRT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Vaxart to Host Upcoming Conference Calls

    Full year 2025 business update and financial results conference call to be held March 12 at 4:30 p.m. ET Stockholder fireside chat to be held on March 13 at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., March 03, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ:VXRT) today announced it will host two upcoming webcast conference calls. Full Year 2025 Business Update and Financial ResultsVaxart will provide a business update and report financial results for the full year ended December 31, 2025, after the market close on Thursday, March 12, 2026. The Vaxart senior management team will host a conference call on the same day, beginning at 4:30 p.m. ET. / 1:30 p.m. PT. The full year financial resul

    3/3/26 4:01:00 PM ET
    $VXRT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate Developments

    Net product revenues for the full year 2025 totaled $1,864.3 million, consisting of $965.6 million of PMO net product revenue and $898.7 million of ELEVIDYS net product revenue Net product revenues for the fourth quarter 2025 totaled $369.6 million, consisting of $259.2 million of PMO net product revenue and $110.4 million of ELEVIDYS net product revenue Following refinancing of 2027 notes and corporate restructuring, overall financial position and capital structure strengthened to support full investment in our pipeline and marketed therapies Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for

    2/25/26 4:05:00 PM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATNX
    $AUTL
    $BBLN
    $ELOX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Equillium Inc.

    SC 13G/A - Equillium, Inc. (0001746466) (Subject)

    11/14/24 9:50:36 PM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Larimar Therapeutics Inc.

    SC 13G/A - Larimar Therapeutics, Inc. (0001374690) (Subject)

    11/14/24 5:05:19 PM ET
    $LRMR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Autolus Therapeutics plc

    SC 13G/A - Autolus Therapeutics plc (0001730463) (Subject)

    11/14/24 4:32:31 PM ET
    $AUTL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care